证券日报网讯2月24日，东材科技（601208）在互动平台回答投资者提问时表示，近年来，公司持续加 大海外市场的开拓力度，部分产品出口欧盟地区，但整体营收占比较小。 ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 有投资者在互动平台向亚邦股份提问："公司近几年与国内外客户均建立了联系，请问近两年是否出口 欧盟国家？" 针对上述提问，亚邦股份回应称："感谢您的关注与提问，公司产品有出口欧盟国家。" 作者：公告君 ...

格隆汇2月11日丨亚邦股份(603188.SH)在投资者互动平台表示，公司产品有出口欧盟国家。 ...

（记者 张明双） 每经AI快讯，航天晨光（600501.SH）1月30日在投资者互动平台表示，近两年公司产品零星出口欧盟 地区，2025年向爱尔兰出口汽车排气管约86万元，收入占比很小，销售方式为直接出口。 ...

格隆汇1月29日丨万泰生物(603392.SH)在投资者互动平台表示，公司产品近年有出口欧盟国家，是以境 内主体直接向欧盟客户出口为主。 ...

证券日报网讯 1月16日，鄂尔多斯（600295）在互动平台回答投资者提问时表示，公司产品出口部分欧 盟国家，在公司整体营业收入中的占比较小，以境内主体直接向欧盟客户出口。 ...

Core Viewpoint - The company has confirmed that its export business primarily serves clients such as RWC, Watts, Oatey, Sioux Chief, Mosack, and Home Depot, and it is actively engaged in the European market [2] Group 1 - The company's products are mainly targeted at markets in the United States and Europe [2]

Core Viewpoint - The company, Xiaoming Co., Ltd. (300967.SZ), has established a strong export relationship with Mongolia, achieving over 50% market share in the local egg-laying hen industry since 2008 [1] Group 1: Export Strategy - In 2024, the company's product export destination will be Mongolia [1] - The collaboration with Mongolian clients began in 2008, indicating a long-term partnership [1] Group 2: Market Position - The company has achieved a market share exceeding 50% in Mongolia, demonstrating its significant presence in the local egg-laying hen industry [1] - The partnership has provided strong support for the development of the egg-laying hen industry in Mongolia [1]

Group 1: Company Overview - The company focuses on high-barrier generic drugs, with a leading position in the research and development pipeline, particularly in products like pre-filled methotrexate injection [2] - The product lineup includes potassium chloride sustained-release tablets and various formulations of potassium chloride, achieving a multi-formulation product combination [2] Group 2: Research and Development - The company’s project initiation standards are based on core therapeutic areas and existing production capacity, focusing on products with fewer applications and technical barriers to ensure competitive advantages [3] - R&D costs for generic drugs are generally lower than those for original drugs, influenced by the complexity of development [3] Group 3: Market and Sales - The company has one product, Luguapeptide injection, with annual revenue exceeding 5,000,000 that is not included in the medical insurance list, maintaining stable market share [3] - Sales are primarily through hospitals, with potassium chloride sustained-release tablets also sold in retail pharmacies and e-commerce platforms, although the latter accounts for a smaller share [3] Group 4: Product Expansion and Future Plans - The company is exploring further expansion in traditional Chinese medicine (TCM) products, with a dedicated business development team researching compatible products [4] - The product Pemabertan tablets are expected to be launched in the following year [4] Group 5: Financial and Shareholder Information - The company has not distributed dividends due to negative retained earnings and has implemented a share buyback plan, utilizing 8,000,000 yuan to repurchase 3,230.72 million shares, representing 1.42% of total share capital [5] - The company is currently without a controlling shareholder due to the bankruptcy of the previous major shareholder, with shares auctioned off in November 2025 [5]

卓然股份（688121.SH）12月17日在投资者互动平台表示，公司近两年有产品出口欧盟国家，但因行业 周期性波动和全球经济环境变化，出口业务整体占比较低。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：注意到贵公司覆盖欧美、中东、东南亚等地区，请问 近两年是否出口欧盟国家？ ...